Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
| Autor: | Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., Desmoulins, I., Tharin, Z., Renaud, E., Bertho, M., Benderra, M-A, Delaloge, S., Robert, L., Cottu, P., Pierga, J. Y., Loirat, D., Bertucci, A., Renouf, B., Bidard, F. C., Lerebours, F. |
|---|---|
| Zdroj: | Oncogene; 20230101, Issue: Preprints p1-1, 1p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink